A Dry Powder Platform for Thermostable, Adjuvanted, Nasal Vaccines
Vehring R, McClary W, Chen J, Gerhardt A, Martin AR, Aisenstat M, Wang H, Duong K, Shepard K, Hosseini S, Fox CB.
Respiratory Drug Delivery 2024. Volume 1, 2024: 59-65.
Abstract:
Increasing antimicrobial resistance, the substantial infectious disease burden in developing countries, and pandemic threats motivate the development of vaccines suitable for global use. A dry powder platform based on engineered particles made of trehalose and an optional shell former, in combination with inexpensive, single-use nasal delivery devices has been explored for this purpose. The platform was compatible with three different adjuvanted vaccine systems and subunit antigens as well as a nucleic acid antigen, enabling thermostability on storage, robustness on administration and efficient delivery to the nose. Aided by predictive models, the platform is straightforward to develop, scalable to high-throughput manufacturing, and compatible with existing development infrastructure.
I have a subscription
Log in for instant access.
I do not have a subscription
Purchase Article (in PDF format)
